These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells. D'Alimonte I; Nargi E; Zuccarini M; Lanuti P; Di Iorio P; Giuliani P; Ricci-Vitiani L; Pallini R; Caciagli F; Ciccarelli R Purinergic Signal; 2015 Sep; 11(3):331-46. PubMed ID: 25976165 [TBL] [Abstract][Full Text] [Related]
4. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide. Xu X; Zheng Y; Luo L; You Z; Chen H; Wang J; Zhang F; Liu Y; Ke Y Cell Death Dis; 2024 May; 15(5):318. PubMed ID: 38710703 [TBL] [Abstract][Full Text] [Related]
5. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925 [TBL] [Abstract][Full Text] [Related]
6. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863 [TBL] [Abstract][Full Text] [Related]
7. Induction Therapy of Retinoic Acid with a Temozolomide-Loaded Gold Nanoparticle-Associated Ultrasound Effect on Glioblastoma Cancer Stem-Like Colonies. Fadera S; Chen PY; Liu HL; Lee IC ACS Appl Mater Interfaces; 2021 Jul; 13(28):32845-32855. PubMed ID: 34235925 [TBL] [Abstract][Full Text] [Related]
8. Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells. Chen JC; Lee IN; Huang C; Wu YP; Chung CY; Lee MH; Lin MH; Yang JT BMC Cancer; 2019 Aug; 19(1):756. PubMed ID: 31370819 [TBL] [Abstract][Full Text] [Related]
9. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme. Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide. Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977 [TBL] [Abstract][Full Text] [Related]
11. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2. Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849 [TBL] [Abstract][Full Text] [Related]
12. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma. Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952 [TBL] [Abstract][Full Text] [Related]
13. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446 [TBL] [Abstract][Full Text] [Related]
14. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma. Chen Z; Wei X; Shen L; Zhu H; Zheng X Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207 [TBL] [Abstract][Full Text] [Related]
15. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
16. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide. Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. Liang H; Chen Z; Sun L Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274 [TBL] [Abstract][Full Text] [Related]
18. BMP4 and Temozolomide Synergize in the Majority of Patient-Derived Glioblastoma Cultures. Verploegh ISC; Conidi A; El Hassnaoui H; Verhoeven FAM; Korporaal AL; Ntafoulis I; van den Hout MCGN; Brouwer RWW; Lamfers MLM; van IJcken WFJ; Huylebroeck D; Leenstra S Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337661 [TBL] [Abstract][Full Text] [Related]
19. Persistent HCMV infection of a glioblastoma cell line contributes to the development of resistance to temozolomide. Singh P; Neumann DM Virus Res; 2020 Jan; 276():197829. PubMed ID: 31790777 [TBL] [Abstract][Full Text] [Related]
20. NADPH Oxidase Subunit CYBB Confers Chemotherapy and Ferroptosis Resistance in Mesenchymal Glioblastoma via Nrf2/SOD2 Modulation. Su IC; Su YK; Setiawan SA; Yadav VK; Fong IH; Yeh CT; Lin CM; Liu HW Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]